Before designing anything, read the last three access decisions word for word — the letter, not the internal summary. The question raised is usually narrow, specific, and considerably narrower than the programme being scoped against it.
What tends to come up
- Durability beyond twelve months, where the pivotal trial stopped at twelve.
- Adherence in a real-world population rather than a trial one.
- Total cost of care including the setting of administration.
- Comparative outcomes in a subgroup the trial under-enrolled.
A rigorous study answering a different question makes a good publication. Matching the question makes it an access lever as well, and the incremental cost of aligning the two at design time is usually small.
Design choices that decide how it lands
Looks right
- The comparator the payer already uses
- Endpoint and analysis plan pre-specified, and stated
- The population you could not observe, described plainly
- Total cost of care, including administration setting
Worth questioning
- A comparator chosen for a favourable contrast
- Post-hoc findings introduced during negotiation
- A clean result with an unexplained denominator
- Drug cost considered in isolation
Where the calendar actually goes
Analysis is the short part. Establishing which claims, EHR and registry assets can be linked lawfully, then agreeing terms, is where the months sit. Running that procurement alongside protocol design rather than after it is the largest schedule saving available in most programmes.
The strongest evidence package is usually the one that names its own weakest link first.
Sources
Real-World Evidence programmeU.S. Food and Drug AdministrationNews and guidanceNational Institute for Health and Care Excellence
Value and access practicePrecisionNeXT